Get started
Author

Lenuta Micsa

Observed name: L. Micsa
Observed institution: Biogen (United States)
OpenAlex ID: A5037497889
TRANSCEND: A Phase 3 Trial of the Anti-CD38 Antibody Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection
2025 · G. Bohmig, K. Budde, et al. · American Journal of Transplantation · 3
Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
2023 · Sam Kant, Dixon B. Kaufman, et al. · Trials · 1
PDF
Transcend and Transpire: Phase 3 and 2 Trials of the Anti-CD38 Antibody Felzartamab in Kidney Transplant Recipients with Antibody-Mediated Rejection or Isolated Microvascular Inflammation
2026 · G.A. Böhmig, K. Budde, et al. · American Journal of Transplantation
Establishing a Central Pathology Review Process and Adjudication Framework to Standardize Biopsy-Based Endpoints in Clinical Trials
2026 · M. Mengel, A. Demetris, et al. · American Journal of Transplantation
MDR-101-MLK Update: Operational Immune Tolerance Achieved in Living Related HLA-Matched Kidney Transplant Recipients
2023 · Dixon Kaufman, Mark D. Stegall, et al. · Journal of the American Society of Nephrology
Works count: 5
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type